INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Inte...

APVO shares rose 46.10% to $2.06 after promising clinical results, but the stock has dropped 98.84% over the past year.

-SEC Filing

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable s...

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor canc...

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for preci...

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(8.40) per share which beat the analyst consensus estimate of $...

-SEC Filing

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...